EUVIMEDEUVIMED entdecken
Open Access

Out-of-Pocket Drug Costs for Medicare Beneficiaries With Cardiovascular Risk Factors Under the Inflation Reduction Act

Prihatha R Narasimmaraj, Andrew Oseran, Archana Tale, Jiaman Xu, Utibe R Essien, Dhruv S Kazi, Robert W Yeh, Rishi K Wadhera

Journal of the American College of Cardiology · 2023-04 · 81 (15) · 1491-1501

DOI: 10.1016/j.jacc.2023.02.002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American College of Cardiology, 2023-04. Verfasst von Prihatha R Narasimmaraj und 7 weiteren Autor:innen. Beteiligte Einrichtung: Richard A. and Susan F. Smith Center for Outcomes Research, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, U…. Hauptthemen laut MEDLINE: Prescription Drugs, Medicare Part D, Cardiovascular Diseases. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: High out-of-pocket prescription drug costs contribute to financial toxicity, medication nonadherence, and adverse cardiovascular (CV) outcomes. Policymakers recently passed the Inflation Reduction Act, which will cap Medicare out-of-pocket drug costs at $2,000/year and expand full low-income subsidies (LIS). It is unclear how these provisions will affect Medicare beneficiaries with CV risk factors and/or conditions. OBJECTIVES: The authors sought to characterize the population of Medicare beneficiaries with CV risk factors/conditions experiencing out-of-pocket prescription drug costs >$2,000/year and estimate their potential savings under the Inflation Reduction Act's spending cap; identify sociodemographic characteristics associated with out-of-pocket costs >$2,000/year; and characterize beneficiaries newly eligible for LIS under the Inflation Reduction Act. METHODS: This was a cross-sectional study of Medicare beneficiaries aged ≥65 years with ≥1 CV risk factor/condition from 2016 to 2019. RESULTS: An annual estimated 34,056,335 ± 855,653 Medicare beneficiaries (mean ± SE) had ≥1 CV risk factor/condition, of whom 1,020,484 ± 77,055 experienced out-of-pocket drug costs >$2,000/year. The likelihood of experiencing out-of-pocket drug costs >$2,000/year was lower among adults ≥75 years vs 65 to 74 years (adjusted OR: 0.67; 95% CI: 0.49-0.93) and for low-income vs higher-income adults. Among beneficiaries currently spending >$2,000/year, estimated median out-of-pocket drug savings would be $855/year and total annual savings $1,723,031,307 ± $91,150,609 under the Inflation Reduction Act. An estimated 1,289,861 beneficiaries would also become newly eligible for LIS. CONCLUSIONS: More than 1 million older adults with CV risk factors and/or conditions spend >$2,000/year out-of-pocket on prescription drugs and will likely benefit from the Inflation Reduction Act's cap, with estimated total out-of-pocket savings of $1.7 billion/year, while another 1.3 million will also become newly eligible for LIS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prescription DrugsMedicare Part DCardiovascular DiseasesHumansAgedUnited StatesHealth ExpendituresDrug CostsCross-Sectional StudiesRisk Factors

Stichwörter der Autor:innen

MedicarePart Dcardiovascular diseasecardiovascular risk factorslow-income subsidiesmedicationsout-of-pocket costsprescription drugs

Substanzen

Prescription Drugs

Autor:innen und Institutionen

  • Richard A. and Susan F. Smith Center for Outcomes Research, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA; Department of Medicine, Brigham and Women's Hospital and Harvard M…
  • Richard A. and Susan F. Smith Center for Outcomes Research, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA; Division of Cardiology, Massachusetts General Hospital and Harvard…
  • Richard A. and Susan F. Smith Center for Outcomes Research, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
  • Division of General Internal Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA; Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvan…
  • Richard A. and Susan F. Smith Center for Outcomes Research, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA. Electronic address: rwadhera@bidmc.harvard.edu.

Förderung

  • NHLBI NIH HHS

Zitieren

APA

Narasimmaraj, P. R., Oseran, A., Tale, A., Xu, J., Essien, U. R., Kazi, D. S., Yeh, R. W., & Wadhera, R. K. (2023). Out-of-Pocket Drug Costs for Medicare Beneficiaries With Cardiovascular Risk Factors Under the Inflation Reduction Act. Journal of the American College of Cardiology, 81(15), 1491-1501. https://doi.org/10.1016/j.jacc.2023.02.002

Vancouver

Narasimmaraj PR, Oseran A, Tale A, Xu J, Essien UR, Kazi DS, et al. Out-of-Pocket Drug Costs for Medicare Beneficiaries With Cardiovascular Risk Factors Under the Inflation Reduction Act. Journal of the American College of Cardiology. 2023;81(15):1491-1501. doi:10.1016/j.jacc.2023.02.002

BibTeX
@article{Narasimmaraj2023,
  author = {Narasimmaraj, Prihatha R and Oseran, Andrew and Tale, Archana and Xu, Jiaman and Essien, Utibe R and Kazi, Dhruv S and Yeh, Robert W and Wadhera, Rishi K},
  title = {Out-of-Pocket Drug Costs for Medicare Beneficiaries With Cardiovascular Risk Factors Under the Inflation Reduction Act},
  journal = {Journal of the American College of Cardiology},
  year = {2023},
  volume = {81},
  number = {15},
  pages = {1491--1501},
  doi = {10.1016/j.jacc.2023.02.002}
}
Kostenlos starten →